Immediate Impact
14 from Science/Nature 63 standout
Citing Papers
Medical, surgical, and physical treatments for Parkinson's disease
2024 Standout
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
2023 Standout
Works of Ronald Brenner being referenced
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
2021
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ronald Brenner | 908 | 306 | 194 | 278 | 60 | 1.5k | |
| Linda Beauclair | 1116 | 313 | 342 | 243 | 43 | 2.1k | |
| Joseph F. Lipinski | 859 | 228 | 230 | 336 | 42 | 1.7k | |
| Nathan S. Kline | 630 | 326 | 279 | 401 | 119 | 1.6k | |
| Richard L. Borison | 1056 | 374 | 307 | 539 | 66 | 1.9k | |
| Matthias J. Müller | 1004 | 357 | 142 | 189 | 60 | 1.9k | |
| J. Ananth | 725 | 258 | 260 | 467 | 92 | 1.8k | |
| A. Klimke | 687 | 242 | 171 | 280 | 79 | 1.6k | |
| Jack Hirschowitz | 804 | 160 | 136 | 273 | 63 | 1.4k | |
| Jun Ishigooka | 731 | 281 | 240 | 192 | 120 | 1.6k | |
| Jeffrey M. Goldstein | 761 | 215 | 271 | 551 | 66 | 1.5k |
All Works
Loading papers...